종양 정밀의료 시장 : 표적 암 유형별, 투여 경로별, 분자 유형별, 약제 클래스별, 주요 지역, 신흥 국가 시장, 판매 예측 : 업계 동향과 세계 예측(-2035년)

Oncology Precision Medicine Market by Type of Cancer Targeted, Route of Administration, Type of Molecule, Drug Class, Key Geographical Regions, Leading Drug Developers and Sales Forecast: Industry Trends and Global Forecasts, Till 2035

US $ 4,799 ￦ 6,943,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,999 ￦ 10,126,000

PDF (One-Location Site License)

PDF 보고서를 동일 사업장의 특정 사업 부문에 속한 모든 분들이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,599 ￦ 15,335,000

PDF (Department License)

PDF 보고서를 부서 단위로 12명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 17,999 ￦ 26,042,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계 종양 정밀의료 시장 규모는 2035년까지 예측 기간 동안 8.5%의 연평균 복합 성장률(CAGR)로 확대되어 현재 1,479억 달러에서 2035년까지 3,640억 달러로 성장할 것으로 예상됩니다.

암은 가장 치명적인 질병 중 하나로 인식되고 있으며, 전 세계적으로 약 2,000만 명이 새로 발병하고 1,000만 명이 사망하는 등 심각한 피해자를 발생시키고 있습니다. 세계보건기구(WHO)에 따르면, 2040년까지 암 부담은 60% 가까이 증가할 것으로 예상됩니다. 현재 수술, 방사선 치료, 화학 요법, 호르몬 치료, 면역 요법, 나노 치료와 같은 비전통적 또는 보완적 치료법을 포함한 여러 가지 전통적인 접근법이 이러한 원인 변수를 치료하는 데 사용할 수 있습니다. 그러나 이러한 접근법으로는 내재적 발암성 유전자 이상에 대응할 수 없습니다. 왜냐하면 이러한 이상은 환자 개개인에게 고유한 것이기 때문입니다. 이 문제를 해결하기 위해 개인맞춤의료로 알려진 정밀의료가 가능한 해결책으로 등장했습니다. 정밀의료의 개념은 종양의 특성, 유전자 데이터, 생활습관, 환경적 영향을 고려하여 맞춤형 의약품을 제공하는 것으로, 획일적인 접근 방식에서 탈피하여 종양 질환 치료에 있어 큰 잠재력을 가지고 있습니다. 현재 진행 중인 기술 혁신의 속도와 개인 맞춤형 의료에 대한 선호도가 높아짐에 따라, 종양 정밀의료 시장은 향후 주목할 만한 성장을 이룰 것으로 예상됩니다.

현재 전 세계적으로 125개 이상의 의약품 개발 기업이 다양한 암을 타겟으로 한 암 분야 정밀의료 개발에 매진하고 있으며, 이들 개발 기업의 약 90%가 선진 지역에 본사를 두고 있습니다. 암 분야 정밀의료 중 55% 가량이 상용화되어 있으며, 그 중 혈액암을 타겟으로 하는 것은 28%에 육박하고 있습니다.

전임상 및 탐색 단계에 있는 암 분야 정밀치료제의 약 85%는 저분자 화합물이며, 그 중 30% 이상이 키나아제 단백질을 표적으로 삼고 있습니다. 암 분야 정밀 의약품 파이프라인을 확대하기 위해 이 분야의 제휴 활동은 지난 5년간 연평균 16%의 높은 성장세를 보이고 있습니다.

암에서 정밀의료는 부작용이 적고 치료 효과가 높다는 장점이 있기 때문에 가까운 미래에 이러한 약제에 대한 선호도가 꾸준히 증가할 것으로 예상됩니다.

세계의 종양 정밀의료 시장에 대해 조사했으며, 시장 개요와 함께 표적 암 유형별/투여 경로별/분자 유형별/약제 유형별/지역별 동향, 시장 진출기업 프로파일 등을 정리하여 전해드립니다.

목차

제1장 서문

제2장 조사 방법

제3장 경제 및 기타 프로젝트 특유의 고려사항

제4장 주요 요약

제5장 서론

제6장 종양 정밀의료 시장 : 시장 구도

제7장 상세한 기업 개요

• 본 장의 개요
• AstraZeneca
• Genentech
• Jiangsu Hengrui Pharmaceuticals
• Johnson &Johnson Innovative Medicine
• Novartis
• Pfizer
• SpringWorks Therapeutics

제8장 기업 개요

• 본 장의 개요
• AbbVie
• Anticancer Bioscience
• Astellas Pharma
• Bayer
• Blueprint Medicines
• Bristol Myers Squibb
• Eli Lilly
• Erasca
• GlaxoSmithKline
• Hutchmed
• IDEAYA Biosciences
• Merck
• Repare Therapeutics
• Roche
• Seagen
• Takeda Pharmaceutical
• VERAXA Biotech
• VRise Therapeutics

제9장 파트너십 및 협업

제10장 임상시험 분석

제11장 사례 연구 : 종양 정밀의료 어세이 키트

제12장 사례 연구 : 정밀의료에서 사용되는 기술

제13장 시장에 대한 영향 분석 : 성장 촉진요인 및 억제요인, 기회, 과제

제14장 세계의 종양학 정밀의료 시장

제15장 종양 정밀의료 시장, 표적 암 유형별

제16장 종양 정밀의료 시장, 투여 경로별

제17장 종양 정밀의료 시장, 분자 유형별

제18장 종양 정밀의료 시장, 약제 클래스별

제19장 종양 정밀의료 시장, 주요 지역별

제20장 종양 정밀의료 시장, 의약품 판매 예측

제21장 종양 정밀의료 시장, 의약품 개발 기업별

제22장 결론

제23장 주요 인사이트

제24장 부록 1 : 표 형식 데이터

제25장 부록 2 : 기업 및 단체 리스트

LSH

영문 목차

영문목차

ONCOLOGY PRECISION MEDICINE MARKET: OVERVIEW

As per Roots Analysis, the global oncology precision medicine market is estimated to grow from USD 147.9 billion in the current year to USD 364 billion by 2035, at a CAGR of 8.5% during the forecast period, till 2035.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Cancer Targeted

• Bladder Cancer
• Blood / Hematologic Cancer
• Breast Cancer
• Cervical Cancer
• Gastrointestinal Cancer
• Head and Neck Squamous Cell Cancer
• Lung Cancer
• Skin Cancer
• Others

Route of Administration

• Oral
• Intravenous
• Others

Type of Molecule

• Small Molecules
• Biologics

Drug Class

• Kinase Inhibitors
• Enzyme Inhibitors
• Immune Checkpoint Inhibitors
• Others

Leading Drug Developers

• Merck
• Pfizer
• AstraZeneca
• Johnson & Johnson Innovative Medicine
• Genentech

Key Geographical Regions

• North America (US, Canada)
• Europe (France, Germany, Italy, Spain and UK)
• Asia (China, Japan, Korea and India)
• Middle East and North Africa (UAE, Israel, Qatar and Rest of Middle East and North Africa)
• Latin America (Brazil, Argentina, Chile and Rest of Latin America)

ONCOLOGY PRECISION MEDICINE MARKET: GROWTH AND TRENDS

Cancer is recognized as one of the deadliest diseases, accounting for an alarming global toll of approximately 20 million new cases and 10 million fatalities. According to the World Health Organization, the cancer burden is anticipated to rise by nearly 60 % by 2040. Currently, several conventional approaches, including surgery, radiation therapy, chemotherapy and nonconventional or complementary therapeutic methods, including hormone therapy, immunotherapy and nanotherapy are available for treating these causative variables. However, these approaches are unable to deal with intrinsic carcinogenic genetic abnormalities, owing to the fact that these irregularities are unique to each individual patient. In order to address this, precision medicine, often known as personalized medicine, emerged as a possible solution, which uses genomic knowledge to provide gene-targeted diagnostics and therapeutics. The concept of precision medicine takes into account the tumor features, genetic data, lifestyle and environmental effects to provide tailored medicines and holds significant potential in treating oncological disorders by shifting away from a one-size-fits-all approach. Given the ongoing pace of innovation, and increasing preference for personalized healthcare, the oncology precision medicine market is poised to experience a noteworthy growth in the foreseen future.

ONCOLOGY PRECISION MEDICINE MARKET: KEY INSIGHTS

The report delves into the current state of the oncology precision medicine market and identifies potential growth opportunities within the industry. Some key findings from the report include:

1. Presently over 125 drug developers, worldwide, are engaged in developing oncology precision medicines targeting various cancers; around 90% of these developers are headquartered in developed geographies.

2. Close to 55% of the oncology precision medicines have been commercialized; of these, close to 28% of the drugs target blood / hematologic type of cancer.

3. Around 85% oncology precision medicines in the preclinical and discovery stages of development are small molecules; of these, more than 30% of the drugs target kinase proteins.

4. In pursuit of expanding the oncology precision medicines pipeline, the partnership activity in this domain has witnessed substantial growth with an annualized rate of 16% over the last five years.

5. Close to one million patients have been recruited / enrolled in clinical trials, registered for the evaluation of oncology precision medicines, across different geographies.

6. Majority of the oncology precision medicine assay kits developers are headquartered in North America; further, more than 30% of the market is captured by large players established post-1990.

7. Around 80% of oncology precision medicine assay kits are diagnostic tests; over 55% of such kits can diagnose, prognose and predict various cancers and provide results within ten days.

8. Owing to the advantages offered by precision medicines in cancer, along with lesser side effects and high response rate, the preference for such drugs will steadily increase in foreseeable future.

9. With the rapid increase in the demand for gene-targeted drugs in the treatment of cancer, the opportunity for companies developing oncology precision medicines is poised to grow at a CAGR of close to 10%.

ONCOLOGY PRECISION MEDICINE MARKET: KEY SEGMENTS

Blood / Hematologic Cancer Occupies the Largest Share of the Oncology Precision Medicine Market

Based on target cancer, the market is segmented into bladder cancer, blood / hematologic cancer, breast cancer, cervical cancer, gastrointestinal cancer, head and neck squamous cell cancer, lung cancer, skin cancer and others. At present, blood / hematologic cancer segment holds the maximum share of the oncology precision medicine market. This can be attributed to the high incidence rate of blood / hematologic cancer, accounting for approximately 1.24 million cases worldwide. It is worth highlighting that the precision oncology market for gastrointestinal cancer is likely to grow at a relatively higher CAGR.

Oral Route of Administration is the Fastest Growing Segment of the Oncology Precision Medicine Market During the Forecast Period

Based on the route of administration, the market is segmented into oral and intravenous route of administration. It is worth highlighting that in the coming years, the oral route is anticipated to grow at a relatively faster pace. This can be attributed to the various advantages offered by oral routes of administration, such as non-invasiveness, higher patient compliance and ease of administration.

Biologics Occupy the Largest Share of the Oncology Precision Medicine Market

Based on the type of molecule, the market is segmented into small molecules and biologics. At present, biologics captures the highest share of the oncology precision medicine market. However, in the coming years, small molecules are anticipated to grow at a relatively faster pace. This can be attributed to the ability of small molecules to easily pass through the cell membranes, enabling selective targeting of biomarkers expressed on the tumor cells.

Kinase Inhibitor Segment is Likely to Dominate the Oncology Precision Medicine Market During the Forecast Period

Based on the drug class, the market is segmented into kinase inhibitors, enzyme inhibitors, immune checkpoint inhibitors and others. It is worth highlighting that, at present, kinase inhibitors hold a larger share of the oncology precision medicine market. This trend is likely to remain the same in the coming decade.

North America Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, Asia, Middle East and North Africa, and Latin America. The majority of the share is expected to be captured by drug developers based in North America. It is worth highlighting that, over the years, the market in Asia-Pacific is expected to grow at a higher CAGR. This can be primarily attributed to the low cost investment for conducting clinical trials in Asian countries.

Example Players in the Oncology Precision Medicine Market

• AbbVie
• Anticancer Bioscience
• Astellas Pharma
• AstraZeneca
• Bayer
• Blueprint Medicines
• Bristol Myers Squibb
• Eli Lilly
• Erasca
• Genentech
• GlaxoSmithKline
• Hutchmed
• IDEAYA Biosciences
• Jiangsu Hengrui Pharmaceuticals
• Johnson & Johnson Innovative Medicine
• Merck
• Novartis
• Pfizer
• Repare Therapeutics
• Roche
• Seagen
• SpringWorks Therapeutics
• Takeda Pharmaceutical
• VERAXA Biotech GmbH
• VRise Therapeutics

ONCOLOGY PRECISION MEDICINE MARKET: RESEARCH COVERAGE

• Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the oncology precision medicine market, focusing on key market segments, including [A] type of cancer targeted, [B] route of administration, [C] type of molecule, [D] drug class, [E] key geographical regions and [F] leading drug developers.
• Market Landscape: A comprehensive evaluation of commercialized and clinical stage oncology precision medicines, considering various parameters, such as [A] stage of development, [B] approval body, [C] approval region, [D] drug designation, [E] type of molecule, [F] drug class, [G] route of administration, [H] dosage regimen, [I] patient population and [K] type of cancer targeted. Furthermore, the chapter includes a detailed analysis of the current landscape of discovery and preclinical stage oncology precision medicines, based on several relevant parameters, such as [L] stage of development, [M] type of molecule, [N] drug class and [O] type of cancer targeted. Additionally, the chapter features information on various drug developers, along with analysis based on multiple parameters, such as [P] year of establishment, [Q] company size and [R] location of headquarters.
• Company Profiles: In-depth profiles of key industry players engaged in oncology precision medicine market, focusing on [A] company overviews, [B] financial information (if available), [C] oncology precision medicine portfolio, [D] recent developments and [E] an informed future outlook.
• Partnerships and Collaborations: An analysis of partnerships established in this sector, since 2018, covering clinical trial agreements, commercialization agreements, drug development agreements, drug development and commercialization agreements, drug distribution agreements, drug licensing agreements, manufacturing agreements, mergers / acquisitions, process development and manufacturing agreements, research agreements, research and development agreements, service agreements, technology utilization agreements and others.
• Clinical Trial Analysis: Examination of completed, ongoing, and planned clinical studies related to oncology precision medicine based on several parameters, such as [A] trial registration year, [B] number of patients enrolled, [C] trial phase, [D] trial status, [E] target patient population, [F] patient gender, [G] type of cancer targeted, [H] type of sponsor / collaborator, [I] study design, [J] most active sponsor / collaborator (leading industry and non-industry players based on the number of clinical trials sponsored), [K] emerging focus areas and [L] geography.
• Case Study: A general discussion on the precision oncology assay kit developers, providing detailed analysis on various parameters such as [A] stage of development, [B] regulatory certification / compliance, [C] regional availability, [D] type of test, [E] type of sample, [F] principle of biomarker detection, [G] turnaround time, [H] type of cancer targeted and [I] end-user. Further, the chapter features information on various assay kit developers, along with analysis based on multiple parameters, such as [J] year of establishment, [K] company size and [L] location of headquarters.
• Market Impact Analysis: The report analyzes various factors such as drivers, restraints, opportunities, and challenges affecting the market growth.

KEY QUESTIONS ANSWERED IN THIS REPORT

• How many companies are currently engaged in this market?
• Which are the leading companies in this market?
• What kind of partnership models are commonly adopted by industry stakeholders?
• What are the factors that are likely to influence the evolution of this market?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

• Complimentary PPT Insights Packs
• Complimentary Excel Data Packs for all Analytical Modules in the Report
• 10% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

• 1.1. Introduction
• 1.2. Market Share Insights
• 1.3. Key Market Insights
• 1.4. Report Coverage
• 1.5. Key Questions Answered
• 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

• 2.1. Chapter Overview
• 2.2. Research Assumptions
• 2.3. Project Methodology
• 2.4. Forecast Methodology
• 2.5. Robust Quality Control
• 2.6. Key Market Segmentations
• 2.7. Key Considerations
  • 2.7.1. Demographics
  • 2.7.2. Economic Factors
  • 2.7.3. Government Regulations
  • 2.7.4. Supply Chain
  • 2.7.5. COVID Impact / Related Factors
  • 2.7.6. Market Access
  • 2.7.7. Healthcare Policies
  • 2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

• 3.1. Chapter Overview
• 3.2. Market Dynamics
  • 3.2.1. Time Period
    • 3.2.1.1. Historical Trends
    • 3.2.1.2. Current and Forecasted Estimates
  • 3.2.2. Currency Coverage
    • 3.2.2.1. Overview of Major Currencies Affecting the Market
    • 3.2.2.2. Impact of Currency Fluctuations on the Industry
  • 3.2.3. Foreign Exchange Impact
    • 3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
    • 3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
  • 3.2.4. Recession
    • 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
    • 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
  • 3.2.5. Inflation
    • 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
    • 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

• 5.1. Chapter Overview
• 5.2. Precision Medicine
  • 5.2.1. Evolution of Precision Medicine
• 5.3. Oncology Precision Medicine
  • 5.3.1. Oncology Precision Medicine over Traditional Cancer Medicine
  • 5.3.2. Steps Involved in Developing Oncology Precision Medicine
  • 5.3.3. Advantages Associated with Oncology Precision Medicine
    • 5.3.3.1. Benefits to the Patients
    • 5.3.3.2. Benefits to the Healthcare Providers
    • 5.3.3.3. Benefits to the Cancer Researchers
  • 5.3.4. Challenges Associated with Oncology Precision Medicines
  • 5.3.5. Future Perspectives

6. ONCOLOGY PRECISION MEDICINE: MARKET LANDSCAPE

• 6.1. Chapter Overview
• 6.2. Oncology Precision Medicine: Commercialized and Clinical Stage Drugs Market Landscape
  • 6.2.1. Analysis by Stage of Development
  • 6.2.2. Analysis by Approval Body
  • 6.2.3. Analysis by Approval Region
  • 6.2.4. Analysis by Drug Designation
  • 6.2.5. Analysis by Type of Molecule
  • 6.2.6. Analysis by Drug Class
  • 6.2.7. Analysis by Route of Administration
  • 6.2.8. Analysis by Dosage Regimen
  • 6.2.9. Analysis by Patient Population
  • 6.2.10. Analysis by Type of Cancer Targeted
  • 6.2.11. Analysis by Stage of Development and Type of Cancer Targeted
• 6.3. Oncology Precision Medicine: Preclinical and Discovery Stage Drugs Market Landscape
  • 6.3.1. Analysis by Stage of Development
  • 6.3.2. Analysis by Type of Molecule
  • 6.3.3. Analysis by Drug Class
  • 6.3.4. Analysis by Type of Cancer Targeted
• 6.4. Oncology Precision Medicine: Developer Landscape
  • 6.4.1. Analysis by Year of Establishment
  • 6.4.2. Analysis by Company Size
  • 6.4.3. Analysis by Location of Headquarters (Region)
  • 6.4.4. Analysis by Location of Headquarters (Country)
  • 6.4.5. Analysis by Company Size and Location of Headquarters (Region)
  • 6.4.6. Most Active Players: Analysis by Number of Oncology Precision Medicines

7. DETAILED COMPANY PROFILES

• 7.1. Chapter Overview
• 7.2. AstraZeneca
  • 7.2.1. Company Overview
  • 7.2.2. Financial Information
  • 7.2.3. Oncology Precision Medicine Portfolio
  • 7.2.4. Recent Developments and Future Outlook
• 7.3. Genentech
  • 7.3.1. Company Overview
  • 7.3.2. Financial Information
  • 7.3.3. Oncology Precision Medicine Portfolio
  • 7.3.4. Recent Developments and Future Outlook
• 7.4. Jiangsu Hengrui Pharmaceuticals
  • 7.4.1. Company Overview
  • 7.4.2. Oncology Precision Medicine Portfolio
  • 7.4.3. Recent Developments and Future Outlook
• 7.5. Johnson & Johnson Innovative Medicine
  • 7.5.1. Company Overview
  • 7.5.2. Financial Information
  • 7.5.3. Oncology Precision Medicine Portfolio
  • 7.5.4. Recent Developments and Future Outlook
• 7.6. Novartis
  • 7.6.1. Company Overview
  • 7.6.2. Financial Information
  • 7.6.3. Oncology Precision Medicine Portfolio
  • 7.6.4. Recent Developments and Future Outlook
• 7.7. Pfizer
  • 7.7.1. Company Overview
  • 7.7.2. Financial Information
  • 7.7.3. Oncology Precision Medicine Portfolio
  • 7.7.4. Recent Developments and Future Outlook
• 7.8. SpringWorks Therapeutics
  • 7.8.1. Company Overview
  • 7.8.2. Oncology Precision Medicine Portfolio
  • 7.8.3. Recent Developments and Future Outlook

8. SHORT COMPANY PROFILES

• 8.1. Chapter Overview
• 8.2. AbbVie
• 8.3. Anticancer Bioscience
• 8.4. Astellas Pharma
• 8.5. Bayer
• 8.6. Blueprint Medicines
• 8.7. Bristol Myers Squibb
• 8.8. Eli Lilly
• 8.9. Erasca
• 8.10. GlaxoSmithKline
• 8.11. Hutchmed
• 8.12. IDEAYA Biosciences
• 8.13. Merck
• 8.14. Repare Therapeutics
• 8.15. Roche
• 8.16. Seagen
• 8.17. Takeda Pharmaceutical
• 8.18. VERAXA Biotech
• 8.19. VRise Therapeutics

9. PARTNERSHIPS AND COLLABORATIONS

• 9.1. Chapter Overview
• 9.2. Partnership Models
• 9.3. Oncology Precision Medicine: Partnerships and Collaborations
  • 9.3.1. Analysis by Year of Partnership
  • 9.3.2. Analysis by Type of Partnership
  • 9.3.3. Analysis by Year and Type of Partnership
  • 9.3.4. Analysis by Type of Partner
  • 9.3.5. Analysis by Drug Involved
  • 9.3.6. Analysis by Type of Cancer Targeted
  • 9.3.7. Most Active Players: Analysis by Number of Partnerships
  • 9.3.8. Analysis by Geography
    • 9.3.8.1. Local and International Agreements
    • 9.3.8.2. Intracontinental and Intercontinental Agreements

10. CLINICAL TRIAL ANALYSIS

• 10.1. Chapter Overview
• 10.2. Scope and Methodology
• 10.3. Oncology Precision Medicine: Clinical Trial Analysis
  • 10.3.1. Analysis by Trial Registration Year
  • 10.3.2. Analysis of Number of Patients Enrolled by Trial Registration Year
  • 10.3.3. Analysis by Trial Phase
  • 10.3.4. Analysis of Number of Patients Enrolled by Trial Phase
  • 10.3.5. Analysis by Trial Registration Year and Trial Phase
  • 10.3.6. Analysis by Trial Status
  • 10.3.7. Analysis by Trial Registration Year and Trial Status
  • 10.3.8. Analysis by Target Patient Population
  • 10.3.9. Analysis by Patient Gender
  • 10.3.10. Analysis by Type of Cancer Targeted
  • 10.3.11. Analysis by Type of Sponsor / Collaborator
  • 10.3.12. Analysis by Study Design
    • 10.3.12.1. Analysis by Type of Trial Masking
    • 10.3.12.2. Analysis by Type of Intervention Model
    • 10.3.12.3. Analysis by Type of Intervention
    • 10.3.12.4. Analysis by Trial Purpose
  • 10.3.13. Most Active Sponsors / Collaborators: Analysis by Number of Clinical Trials
    • 10.3.13.1. Analysis by Leading Industry Players
    • 10.3.13.2. Analysis by Leading Non-Industry Players
  • 10.3.14. Word Cloud Analysis: Emerging Focus Areas
  • 10.3.15. Analysis by Geography
    • 10.3.15.1. Analysis of Clinical Trials by Geography
    • 10.3.15.2. Analysis of Clinical Trials by Geography and Trial Status
    • 10.3.15.3. Analysis of Patients Enrolled by Geography and Trial Status

11. CASE STUDY: ONCOLOGY PRECISION MEDICINE ASSAY KITS

• 11.1. Chapter Overview
• 11.2. Oncology Precision Medicine: Assay Kits
  • 11.2.1. Analysis by Stage of Development
  • 11.2.2. Analysis by Regulatory Certification / Compliance
  • 11.2.3. Analysis by Regional Availability
  • 11.2.4. Analysis by Type of Test
  • 11.2.5. Analysis by Type of Sample Used
  • 11.2.6. Analysis by Principle of Biomarker Detection
  • 11.2.7. Analysis by Turnaround Time
  • 11.2.8. Analysis by Type of Cancer Targeted
  • 11.2.9. Analysis by Turnaround Time and Type of Cancer Targeted
  • 11.2.10. Analysis by End-user
  • 11.2.11. Analysis by Regional Availability and End-user
  • 11.2.12. Analysis by Type of Cancer Targeted and End-user
• 11.3. Oncology Precision Medicine Assay Kits: Developer Landscape
  • 11.3.1. Analysis by Year of Establishment
  • 11.3.2. Analysis by Company Size
  • 11.3.3. Analysis by Location of Headquarters (Region)
  • 11.3.4. Analysis by Location of Headquarters (Country)
  • 11.3.5. Analysis by Company Size and Location of Headquarters (Region)
  • 11.3.6. Analysis by Business Model
  • 11.3.7. Most Active Players: Analysis by Number of Oncology Precision Medicine Assay Kits

12. CASE STUDY: TECHNOLOGIES USED IN PRECISION MEDICINE

• 12.1. Chapter Overview
• 12.2. Technologies Used in Precision Medicine
  • 12.2.1. Next Generation Sequencing in Precision Medicine
  • 12.2.2. Nanotechnology in Precision Medicine
  • 12.2.3. Molecular Imaging Technologies in Precision Medicine
  • 12.2.4. Omics Technologies in Precision Medicine
  • 12.2.5. Artificial Intelligence (AI) in Precision Medicine
• 12.3. Conclusion

13. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

• 13.1. Chapter Overview
• 13.2. Market Drivers
• 13.3. Market Restraints
• 13.4. Market Opportunities
• 13.5. Market Challenges
• 13.6. Conclusion

14. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET

• 14.1. Chapter Overview
• 14.2. Assumptions and Methodology
• 14.3. Global Oncology Precision Medicine Market, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
• 14.4. Scenario Analysis
  • 14.4.1. Conservative Scenario
  • 14.4.2. Optimistic Scenario
• 14.5. Key Market Segmentations

15. ONCOLOGY PRECISION MEDICINE MARKET, BY TYPE OF CANCER TARGETED

• 15.1. Chapter Overview
• 15.2. Key Assumptions and Methodology
• 15.3. Oncology Precision Medicine Market: Distribution by Type of Cancer Targeted, 2023, 2028 and 2035
  • 15.3.1. Bladder Cancer: Forecasted Estimates (till 2035)
  • 15.3.2. Blood / Hematologic Cancer: Forecasted Estimates (till 2035)
  • 15.3.3. Breast Cancer: Forecasted Estimates (till 2035)
  • 15.3.4. Cervical Cancer: Forecasted Estimates (till 2035)
  • 15.3.5. Gastrointestinal Cancer: Forecasted Estimates (till 2035)
  • 15.3.6. Head and Neck Squamous Cell Cancer: Forecasted Estimates (till 2035)
  • 15.3.7. Lung Cancer: Forecasted Estimates (till 2035)
  • 15.3.8. Skin Cancer: Forecasted Estimates (till 2035)
  • 15.3.9. Other Cancers: Forecasted Estimates (till 2035)
• 15.4. Data Triangulation and Validation

16. ONCOLOGY PRECISION MEDICINE MARKET, BY ROUTE OF ADMINISTRATION

• 16.1. Chapter Overview
• 16.2. Key Assumptions and Methodology
• 16.3. Oncology Precision Medicine Market: Distribution by Route of Administration, 2023, 2028 and 2035
  • 16.3.1. Oral: Forecasted Estimates (till 2035)
  • 16.3.2. Intravenous: Forecasted Estimates (till 2035)
  • 16.3.3. Others: Forecasted Estimates (till 2035)
• 16.4. Data Triangulation and Validation

17. ONCOLOGY PRECISION MEDICINE MARKET, BY TYPE OF MOLECULE

• 17.1. Chapter Overview
• 17.2. Key Assumptions and Methodology
• 17.3. Oncology Precision Medicine Market: Distribution by Type of Molecule, 2023, 2028 and 2035
  • 17.3.1. Small Molecules: Forecasted Estimates (till 2035)
  • 17.3.2. Biologics: Forecasted Estimates (till 2035)
• 17.4. Data Triangulation and Validation

18. ONCOLOGY PRECISION MEDICINE MARKET, BY DRUG CLASS

• 18.1. Chapter Overview
• 18.2. Key Assumptions and Methodology
• 18.3. Oncology Precision Medicine Market: Distribution by Drug Class, 2023, 2028 and 2035
  • 18.3.1. Kinase Inhibitors: Forecasted Estimates (till 2035)
  • 18.3.2. Enzyme Inhibitors: Forecasted Estimates (till 2035)
  • 18.3.3. Immune Checkpoint Inhibitors: Forecasted Estimates (till 2035)
  • 18.3.4. Others: Forecasted Estimates (till 2035)
• 18.4. Data Triangulation and Validation

19. ONCOLOGY PRECISION MEDICINE MARKET, BY KEY GEOGRAPHICAL REGIONS

• 19.1. Chapter Overview
• 19.2. Key Assumptions and Methodology
• 19.3. Oncology Precision Medicine Market: Distribution by Key Geographical Regions, 2023, 2028 and 2035
  • 19.3.1. North America: Forecasted Estimates (till 2035)
    • 19.3.1.1. US: Forecasted Estimates (till 2035)
    • 19.3.1.2. Canada: Forecasted Estimates (till 2035)
  • 19.3.2. Europe: Forecasted Estimates (till 2035)
    • 19.3.2.1. France: Forecasted Estimates (till 2035)
    • 19.3.2.2. Germany: Forecasted Estimates (till 2035)
    • 19.3.2.3. Italy: Forecasted Estimates (till 2035)
    • 19.3.2.4. Spain: Forecasted Estimates (till 2035)
    • 19.3.2.5. UK: Forecasted Estimates (till 2035)
  • 19.3.3. Asia: Forecasted Estimates (till 2035)
    • 19.3.3.1. China: Forecasted Estimates (till 2035)
    • 19.3.3.2. Japan: Forecasted Estimates (till 2035)
    • 19.3.3.3. Korea: Forecasted Estimates (till 2035)
    • 19.3.3.4. India: Forecasted Estimates (till 2035)
  • 19.3.4. Middle East and North Africa: Forecasted Estimates (till 2035)
    • 19.3.4.1. UAE: Forecasted Estimates (till 2035)
    • 19.3.4.2. Israel: Forecasted Estimates (till 2035)
    • 19.3.4.3. Qatar: Forecasted Estimates (till 2035)
    • 19.3.4.4. Rest of Middle east and North Africa: Forecasted Estimates (till 2035)
  • 19.3.5. Latin America: Forecasted Estimates (till 2035)
    • 19.3.5.1. Brazil: Forecasted Estimates (till 2035)
    • 19.3.5.2. Argentina: Forecasted Estimates (till 2035)
    • 19.3.5.3. Chile: Forecasted Estimates (till 2035)
    • 19.3.5.4. Rest of Latin America: Forecasted Estimates (till 2035)
• 19.4. Data Triangulation and Validation

20. ONCOLOGY PRECISION MEDICINE MARKET, SALES FORECAST OF DRUGS

• 20.1. Chapter Overview
• 20.2. Key Assumptions and Methodology
• 20.3. Blockbuster Commercialzied Oncology Precision Medicine Market: Sales Forecast
  • 20.3.1. ADCETRIS(R) Sales Forecast
  • 20.3.2. Alecensa(R) Sales Forecast
  • 20.3.3. ALUNBRIG(R) Sales Forecast
  • 20.3.4. Avastin(R) Sales Forecast
  • 20.3.5. Ayvakit(R) Sales Forecast
  • 20.3.6. Braftovi(R)+ Mektovi(R) Sales Forecast
  • 20.3.7. BRUKINSA(R) Sales Forecast
  • 20.3.8. CALQUENCE(R) Sales Forecast
  • 20.3.9. DARZALEX(R) Sales Forecast
  • 20.3.10. Elunate(R) Sales Forecast
  • 20.3.11. Empliciti(R) Sales Forecast
  • 20.3.12. Enhertu(R) Sales Forecast
  • 20.3.13. IBRANCE(R) Sales Forecast
  • 20.3.14. ICLUSIG(R) Sales Forecast
  • 20.3.15. IMBRUVICA(R) Sales Forecast
  • 20.3.16. IMFINZI(R) Sales Forecast
  • 20.3.17. INLYTA(R) Sales Forecast
  • 20.3.18. Keytruda(R) Sales Forecast
  • 20.3.19. Kadcyla(R) Sales Forecast
  • 20.3.20. LENVIMA(R) / KISPLYX(R) Sales Forecast
  • 20.3.21. Lumakras(R) / Lumykras(R) Sales Forecast
  • 20.3.22. Mekinist(R) Sales Forecast
  • 20.3.23. NERLYNX(R) Sales Forecast
  • 20.3.24. NINLARO(R) Sales Forecast
  • 20.3.25. Opdivo(R) Sales Forecast
  • 20.3.26. Padcev(R) Sales Forecast
  • 20.3.27. Piqray(R) Sales Forecast
  • 20.3.28. Sprycel(R) Sales Forecast
  • 20.3.29. Tabrecta(R) Sales Forecast
  • 20.3.30. Tagrisso(R) Sales Forecast
  • 20.3.31. Tasigna(R) Sales Forecast
  • 20.3.32. Tecentriq(R) Sales Forecast
  • 20.3.33. VENCLEXTA(R) Sales Forecast
  • 20.3.34. Verzenio(R) / Verzenios Sales Forecast
  • 20.3.35. Xospata(R) Sales Forecast
  • 20.3.36. Xtandi(R) Sales Forecast
  • 20.3.37. ZEJULA(R) Sales Forecast
• 20.4. NDA-filed Oncology Precision Medicine Market: Sales Forecast
  • 20.4.1. Apatinib / Rivoceranib Sales Forecast
  • 20.4.2. Elunate(R) Sales Forecast
• 20.5. Phase III Oncology Precision Medicine Market: Sales Forecast
  • 20.5.1. Darovasertib / IDE196 Sales Forecast
    • 20.5.1.1. Darovasertib / IDE196 Regional Sales Forecast
  • 20.5.2. Elenestinib / BLU-263 Sales Forecast
    • 20.5.2.1. Elenestinib / BLU-263 Regional Sales Forecast
  • 20.5.3. Elunate(R) Sales Forecast
    • 20.5.3.1. Elunate(R) Sales Forecast by Type of Cancer Targeted
    • 20.5.3.2. Elunate(R) Regional Sales Forecast
  • 20.5.4. ORPATHYS(R) Sales Forecast
    • 20.5.4.1. ORPATHYS(R) Regional Sales Forecast
  • 20.5.5. Pyrotinib Sales Forecast
    • 20.5.5.1. Pyrotinib Sales Forecast by Type of Cancer Targeted
    • 20.5.5.2. Pyrotinib Regional Sales Forecast
  • 20.5.6. SYD985 / (Vic-) trastuzumab duocarmazine) Sales Forecast
    • 20.5.6.1. SYD985 / (Vic-) trastuzumab duocarmazine) Regional Sales Forecast
  • 20.5.7. ZOLINZA(R) Sales Forecast
    • 20.5.7.1. ZOLINZA(R) Regional Sales Forecast

21. ONCOLOGY PRECISION MEDICINE MARKET, BY LEADING DRUG DEVELOPERS

• 21.1. Chapter Overview
• 21.2. Key Assumptions and Methodology
• 21.3. Oncology Precision Medicine Market: Distribution by Leading Drug Developers
• 21.4. Data Triangulation and Validattion

22. CONCLUSION

23. EXECUTIVE INSIGHTS

• 23.1. Chapter Overview
• 23.2. Company A
  • 23.2.1. Company Snapshot
  • 23.2.2. Interview Transcript
• 23.3. Company B
  • 23.3.1. Company Snapshot
  • 23.3.2. Interview Transcript

24. APPENDIX 1: TABULATED DATA

25. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

관련자료